Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy in humans,
accounting for nearly 40% of all non-Hodgkin lymphomas.
1
In spite of recent advances in monoclonal antibody therapy, up to 40% of patients
eventually relapse and die of their disease after treatment with chemo-immunotherapy
regimens. Given the inability to cure many patients with DLBCL, and the significant
toxicity of current therapies, better treatment strategies are needed. Functional
genomics studies have allowed DLBCLs to be subdivided into biologically and clinically
relevant disease subtypes, which are called germinal center B-cell (GCB-like) type
or activated B-cell (ABC-like) type, based on their transcriptional similarity to
the respective populations of primary B cells.
2
The ABC-like DLBCLs are generally more refractory to treatment than the GCB-like subtype.
In spite of these advances, much remains unknown regarding the genetic basis and pathophysiology
of this aggressive and highly heterogeneous B-cell malignancy.
In this regard, we have recently identified gain of 3q27.2 as being significantly
associated with adverse outcome in DLBCL and linked with the ABC-like subtype.
3
This lesion includes the BCL6 oncogene, but, surprisingly, using integrative analysis
of paired DNA copy number and gene expression microarray data, we found no significant
overexpression of BCL6 transcript in tumors with 3q27 gain, nor did we observe coordinate
repression of previously identified BCL6 target genes in these tumors.
3
Furthermore, transgenic mice that express Bcl6 specifically in mature B cells develop
lymphomas in only a subset of mice,
4
and these tumors align most significantly with the GCB-like stage of murine B-cell
development—a very different phenotype than aggressive human ABC-like DLBCL, in which
genetic alterations of BCL6 are most frequently observed. This observation led us
to hypothesize that BCL6 may function as a “hit-and-run” oncogene that acts at an
early stage of B-cell development to reprogram hematopoietic stem/progenitor cells
(HS/PCs) for malignancy. To test this hypothesis, we generated strains of mice with
restricted expression of this oncogene within HS/PCs.
3
Despite lack of Bcl6 protein expression, mature non-malignant B cells from these mice
show coordinate repression of Bcl6 target genes, suggesting a lasting imprint from
Bcl6-mediated reprogramming within the stem/progenitor compartment. These mice go
on to develop aggressive and clonal B-cell lymphomas that accumulate at a post-germinal
center stage of differentiation, in line with human lymphomas in which BCL6 alterations
are most frequently observed.
3
These results therefore confirm that activity of the Bcl6 oncogene restricted to HS/PCs
can induce malignancies in mice that are of a post-germinal center stage of differentiation.
Bcl6 mediates suppression of target genes via recruitment of factors that epigenetically
modify chromatin. We hypothesized that this may elicit changes in DNA methylation,
a mark that is capable acting in gene silencing memory, and therefore investigated
whether this may be a potential mechanism for Bcl6-medited “hit-and-run” oncogenesis.
Using genome-wide DNA methylation profiling of populations of HS/PCs and mature B-cells
from wild type and Sca1-Bcl6 mice, we identified broad epigenetic changes associated
with the expression of Bcl6 in HS/PCs. Importantly, a significant subset of these
changes were found to be maintained from HS/PCs to mature B cells in Sca1–Bcl6 mice,
resulting in these populations being epigenetically more similar to each other than
to their comparative population from wild-type mice.
3
Together these results suggest that the “hit-and-run” role of Bcl6 activity may be
manifested via epigenetic alterations. This epigenetic memory would maintain gene
expression states through cell generations without a change in DNA sequence and in
the absence of initiating signals.
In conclusion, we have provided the first evidence of a “hit-and-run” role for Bcl6
in the oncogenesis of lymphoma. The implication of these findings is that, if ABC-like
DLBCL occurs via a reprogramming-like mechanism, oncogenes that initiate tumor formation
might be dispensable for tumor cell survival and/or tumor progression. In this context,
mutations that activate oncogenes would have a driving role in the reprogramming process,
but may act as passenger mutations thereafter, or may have a secondary role in evolved
tumor cell clones.
5
,
6
This may provide an explanation for the failure of some modern targeted therapies
to clear tumor stem cells, despite being effective agents against evolved tumor cells.
For instance, BCL6 has emerged as a potentially important therapeutic target in recent
years given its frequent involvement in lymphomagenesis and the fact that specific
BCL6 inhibitors can kill lymphoma cells in vitro and in vivo.
7
If BCL6 was required to maintain lymphoma-repopulating stem cells, then such a BCL6-targeted
therapy might indeed prove effective in eradicating residual tumor cells when translated
to the human setting. On the other hand, the fact that BCL6 can also contribute to
the malignant phenotype through a hit-and-run mechanism dependent on aberrant epigenetic
programming of HS/PCs raises the possibility that tumor cells could emerge that become
BCL6-independent. This prediction is supported by the fact that certain BCL6-positive
DLBCL cell lines such as OCI-Ly8 (which contains a BCL6 translocation) and Karpas
422 are not killed by BCL6 shRNA or BCL6-targeted therapy. From the therapeutic standpoint,
this would indicate the need to combine BCL6 inhibitors with drugs that can kill these
BCL6-independent cells. These concepts are therefore central to the full understanding
of disease genesis and critical for the development of modern therapies aimed at directly
addressing such genetic lesions.
Figure 1. Bcl6 hit-and-run oncogenesis in lymphoma. Transient introduction of Bcl6
into HS/PCs was sufficient to induce ABC-DLBCL lymphoma through specific genetic/epigenetic
changes in HS/PCs that do not interfere with normal B cell development. This model
initially applies to the mouse and the role of BCL6 in human DLBCL progenitors is
still unknown and an area of future investigation.